Anti Human Cd152 Antibody: Reliable Sources for Research and Clinical Use

Discover our revolutionary Anti Human cd152 Antibody, developed and produced by Alpha Lifetech Incorporation. Our antibody is specifically designed to target CD152, a crucial regulator of the immune response. By inhibiting the function of CD152, our antibody can modulate the immune system and potentially enhance immune responses in various therapeutic applications, With a high affinity and specificity for human CD152, our antibody offers researchers and clinicians a powerful tool for studying T-cell activation, tolerance, and immune regulation. It can also be used in the development of novel immunotherapies for cancer, autoimmune diseases, and transplant rejection, At Alpha Lifetech Incorporation, we are committed to delivering high-quality products that meet the needs of the scientific and medical communities. Our Anti Human Cd152 Antibody is rigorously tested to ensure consistent performance and reliability in a variety of experimental settings, Join us in unlocking the potential of immune modulation with our Anti Human Cd152 Antibody. Contact us today to learn more about this groundbreaking product and how it can advance your research and therapeutic development

Hot Selling Product

ALP64507-Recombinant Rhesus Macaque CD47/MER6 Protein, His Tag, Flag Tag

ALP64514-Recombinant Human 5T4/TPBG Protein, Avi Tag, His Tag

ALP64527-Recombinant Human Biotinylated FGL1 Protein, Fc Tag, Avi Tag

ALP64535-Recombinant Human CD33L3/Siglec-15 Protein, mFc Tag

ALP64538-Recombinant Human ANGPTL4/Angiopoietin-like protein 4 Protein, His Tag

ALP64596-Recombinant Human CD152/CTLA-4 Protein, GST Tag

Avoiding Pitfalls Anti Human Cd152 Antibody Supplies the World’s Top Brands Stands Out

In the competitive landscape of biopharmaceuticals, the role of high-quality reagents and antibodies cannot be overstated, especially when it comes to critical research and therapeutic developments. One such essential component is the anti-human CD152 antibody, known for its significance in immunology. However, navigating the market can be fraught with pitfalls, particularly for global buyers seeking reliability and efficacy. At Alpha Lifetech Inc., we understand these challenges and stand out as a trusted supplier, having been founded by a team of scientists with extensive experience in membrane Protein production, nanobody discovery, and monoclonal development. Our commitment to quality is demonstrated through nearly 10,000 meticulously developed reagents, cytokines, and drug-target antibodies. This vast portfolio not only highlights our expertise but also reflects our dedication to providing products that meet the highest industry standards. With rigorous testing and validation processes in place, we ensure that each batch of anti-human CD152 antibodies is consistent and reliable, making them suitable for a wide array of applications, from research to clinical trials. By choosing Alpha Lifetech Inc., global buyers can avoid the common pitfalls of sourcing antibodies that may compromise their work. Our comprehensive customer support and expertise in the field further enhance the purchasing experience, ensuring that clients receive not only superior products but also strategic guidance tailored to their specific needs. Partner with us to access the highest quality anti-human CD152 antibodies and elevate your research to new heights.

Avoiding Pitfalls Anti Human Cd152 Antibody Supplies the World’s Top Brands Stands Out

Attribute	Description	Value
Antibody Type	Monoclonal	-
Target	CD152	-
Origin	Mouse	-
Application	Flow Cytometry	-
Concentration	1 mg/mL	-
Purity	>95%	-
Storage	-20°C	-
Pack Size	100 µg	-

Comparative Analysis of Anti-Human Cd152 Antibody Efficacy Across Different Applications

The chart presented above illustrates the efficacy of Anti-Human Cd152 antibody across five selected applications, showcasing a range of performance from 65% to 90%. Application C stands out with a remarkable efficacy rate of 90%, indicating a superior performance relative to its counterparts. Application B follows closely with an efficacy of 82%. On the other hand, Application D shows the least efficacy rate at 65%, highlighting potential areas for improvement or differentiation in application methods. Each dataset within the chart reflects the varying effectiveness of the antibody in different experimental contexts, providing a clear visual representation of its potential capabilities. Understanding these differences is crucial for researchers and firms when choosing the right application for their specific needs, ensuring they can harness the full potential of this antibody in their work effectively.